Functional Residual Capacity Under Apnoeic Oxygenation with Different Flow Rates in Children
Launched by THOMAS RIVA · Dec 21, 2022
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
High-flow nasal oxygen (HFNO) is the administration of heated, humidified and blended air/oxygen via nasal cannula at rates ≥ 2 L/kg/min. HFNO is an open system that can be used with nasal prongs of different sizes and was developed in neonatal intensive care unit for preterm babies with apnoea as alternative to continuous positive airway pressure (CPAP). Due to its ease of use and safety to apply to a wide range of indication HFNO is increasingly gaining interest for providing respiratory support in paediatric patients and in adults in ICU with respiratory failure. In adult populations, th...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent by legal guardian
- • Paediatric patients undergoing elective surgery requiring general anaesthesia at the Bern University Hospital - Inselspital in Bern
- • Child weight between 10-20kg
- • American Society of Anesthesiology (ASA) physical status 1 \& 2 (healthy child, no severe co-morbidities)
- Exclusion Criteria:
- • Known or suspected difficult intubation
- • Oxygen dependency
- • Congenital heart or lung disease
- • Obesity BMI (kg/m2) \>30
- • High aspiration risk (requiring rapid sequence intubation).
About Thomas Riva
Thomas Riva is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, the organization collaborates with leading researchers and healthcare institutions to design and conduct rigorous clinical trials. Thomas Riva prioritizes ethical standards and patient safety, ensuring that all studies are conducted in compliance with regulatory guidelines. By fostering partnerships and leveraging cutting-edge technologies, Thomas Riva aims to accelerate the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Alexander Fuchs, M.D.
Principal Investigator
Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital,
Thomas Riva, M.D.
Study Director
Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital,
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials